Nibash Budhathoki, MBBS

Nibash Budhathoki practices at UnityPoint Health - St. Luke's in Sioux City, Iowa, part of UnityPoint Health.

Nibash Budhathoki's NPI, 1861876526, was assigned on July 13, 2015. Nibash Budhathoki holds Iowa license MD-48110.

Nibash Budhathoki's primary practice is UnityPoint Health - St. Luke's, at 2720 Stone Park Boulevard, Sioux City, IA 51104 in Woodbury County. The practice phone is (712) 279-3500.

Nibash Budhathoki's primary practice is UnityPoint Health - St. Luke's in Sioux City, Iowa, part of UnityPoint Health. Nibash Budhathoki is also affiliated with The University of Kansas Hospital. The medical group on file is June E. Nylen Cancer Center. Dmand AI also links Nibash Budhathoki to 3 more hospitals, 2 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Nibash Budhathoki practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Nibash Budhathoki's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Nibash Budhathoki is licensed in Iowa.

CMS data shows 93,738 Medicare services from Nibash Budhathoki across 72 procedure codes in 2024, for 785 Medicare patients. Medicare paid $1,958,220 for them.

CMS counts 785 Medicare patients who saw Nibash Budhathoki in 2024. The largest group is 65 to 74, with 343 patients. 75% of them have high blood pressure, and 73% have high cholesterol. 10% are also on Medicaid. Their average risk score is 1.94, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Nibash Budhathoki's median patient age at 71, with 57% women.

In 2024, Nibash Budhathoki wrote 1,734 Medicare Part D claims for 296 patients. 74% of them were for generic drugs. CMS names the drug for 1,429 of them, across 34 drugs with 11 or more claims each, at $5,577,586 in total drug cost. In 2023, CMS named 1,113 claims across 31 drugs.

Nibash Budhathoki accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Nibash Budhathoki as offering telehealth.

Dmand AI links 9 papers to Nibash Budhathoki, published from 2015 to 2021. 2021 was the busiest year, with 2. The most frequent topics are Neoplasms, Second Primary and SEER Program. Nibash Budhathoki has published most often in Anticancer Res. Nibash Budhathoki's most frequent co-authors are Binay Kumar Shah, MD, Douglas Kanter Marks, MD and Sylvia Adams, MD.

CMS Open Payments shows 271 general payments to Nibash Budhathoki from 62 drug and device companies from 2019 to 2025. Food and beverage make up the largest share, 92% of the total. Bristol-Myers Squibb Company paid the most, $552.